A dual GIP/GLP-1 receptor agonist is a medicine that works on two natural hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both hormones are involved in how the body responds to food and help regulate blood sugar.
Because it acts on both pathways, this type of medicine can also affect appetite and how full someone feels, which influences how much they eat. Tirzepatide, sold in Australia under the brand name Mounjaro, is one example, approved for type 2 diabetes and for weight management in eligible adults.
These medicines are only available on prescription and require ongoing check-ups with a doctor. They can cause digestive side effects and aren't right for everyone. A doctor will consider a person's medical history, other medicines, any pregnancy plans and their treatment goals before recommending one.
Book a telehealth consultation with an AHPRA-registered GP for assessment, prescriptions, referrals or advice.
Book ConsultationA dual GIP/GLP-1 receptor agonist is a prescription medicine that acts on two gut hormones involved in blood sugar and appetite control.
No. This glossary explains general health terminology, not your individual symptoms or test results. Speak with a qualified health professional for advice about your circumstances. For a medical emergency, call 000.
Proudly Australian-owned and operated